CL:CA:CNSX-Cresco Labs Inc (CAD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 2.2

Change

-0.02 (-0.90)%

Market Cap

USD 0.77B

Volume

0.06M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections and fruit-forward gummies under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company was incorporated in 1990 and is headquartered in Chicago, Illinois. Address: 400 West Erie Street, Chicago, IL, United States, 60654

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-02 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
GTII:CA Green Thumb Industries Inc

-0.04 (-0.25%)

USD 3.28B
TRUL:CA Trulieve Cannabis Corp

-0.07 (-0.43%)

USD 2.92B
AYR-A:CA Ayr Wellness Inc

+0.01 (+0.41%)

USD 0.28B
PLTH:CA Planet 13 Holdings Inc

N/A

USD 0.26B
GRIN:CA Grown Rogue International Inc

+0.03 (+3.23%)

USD 0.21B
AAWH-U:CA Ascend Wellness Holdings Inc.

-0.02 (-2.50%)

USD 0.17B
JUSH:CA Jushi Holdings Inc

+0.06 (+9.23%)

USD 0.13B
IAN:CA iAnthus Capital Holdings Inc

+0.01 (+50.00%)

USD 0.10B
MRMD:CA MariMed Inc.

N/A

USD 0.09B
FFNT:CA 4Front Ventures Corp

N/A

USD 0.06B

ETFs Containing CL:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 22.91% 64% D 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 22.91% 64% D 70% C-
Trailing 12 Months  
Capital Gain 53.85% 76% C+ 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 53.85% 76% C+ 75% C
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -26.70% N/A N/A 27% F
Dividend Return -26.70% N/A N/A 27% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 38.44% N/A N/A 62% D
Risk Adjusted Return -69.47% N/A N/A 27% F
Market Capitalization 0.77B 97% N/A 100% F

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector